¼¼°èÀÇ Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS) ½ÃÀå
Chromatography Data Systems (CDS)
»óǰÄÚµå : 1795810
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 570 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 7¾ï 7,240¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 5¾ï 410¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS) ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 7¾ï 7,240¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ CDS ¼ÒÇÁÆ®¿þ¾î´Â CAGR 8.5%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 4,400¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. CDS ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 3,730¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS) ½ÃÀåÀº 2024³â¿¡ 1¾ï 3,730¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 11.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 6,470¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.6%¿Í 7.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛÀÌ Çö´ë ½ÇÇè½Ç ȯ°æ¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ(CDS)Àº Å©·Î¸¶Åä±×·¡ÇÇ ÇÁ·Î¼¼½ºÀÇ º¹À⼺, ±ÔÁ¦ Áؼö, µ¥ÀÌÅÍ ¹«°á¼º, ¿öÅ©Ç÷οì ÀÚµ¿È­¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°è ºÐ¼® ½ÇÇè½Ç¿¡¼­ ÇʼöÀûÀÎ µµ±¸°¡ µÇ¾ú½À´Ï´Ù. CDS ¼ÒÇÁÆ®¿þ¾î´Â HPLC, GC, UHPLC µîÀÇ Àåºñ¿¡¼­ µ¥ÀÌÅ͸¦ ¼öÁý, ó¸®, ÀúÀåÇÔÀ¸·Î½á Å©·Î¸¶Åä±×·¡ÇÇ ÀåºñÀÇ Á᫐ ¿ªÇÒÀ» Çϸç, »ùÇà ÁÖÀÔºÎÅÍ °á°ú º¸°í±îÁö Àüü ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÕ´Ï´Ù. Á¦¾à, »ý¸í°øÇÐ, ½ÄÀ½·á, ȯ°æ Å×½ºÆ®, ¼®À¯È­ÇÐ ºÐ¾ß¿¡¼­ °í󸮷® ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®Çϰí ÀçÇö¼ºÀÌ ³ôÀ¸¸ç ±ÔÁ¤À» ÁؼöÇÏ´Â µ¥ÀÌÅÍ ºÐ¼®À» ÃËÁøÇÏ´Â CDSÀÇ ¿ªÇÒÀÌ ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. °Ë»ç½ÇÀº ¼öÀÛ¾÷¿¡ ÀÇÇÑ µ¥ÀÌÅÍ ·Î±ë°ú ´ÜÆíÀûÀÎ ½Ã½ºÅÛ¿¡¼­ ¿©·¯ ÀåºñÀÇ Á¦¾î, µ¥ÀÌÅÍ Áß¾Ó °ü¸®, °í±Þ ºÐ¼®À» Áö¿øÇÏ´Â ÅëÇÕ CDS Ç÷§ÆûÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. FDA, EMA, ISO µî ±ÔÁ¦±â°üÀÇ °¨½Ã °­È­´Â CDS Ç÷§ÆûÀÌ Á¦°øÇÏ´Â °¨»ç ÃßÀû, ÀüÀÚ¼­¸í, ¾ÈÀüÇÑ µ¥ÀÌÅÍ ÀúÀåÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CDS´Â °Ë»ç½ÇÀÌ Ã³¸® ½Ã°£À» ´ÜÃàÇϰí È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ ¸° ÇÁ·¢Æ¼½º¸¦ äÅÃÇÔ¿¡ µû¶ó °£¼ÒÈ­µÈ ¿öÅ©Ç÷οì¿Í Ç¥ÁØÈ­µÈ ÀýÂ÷ÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. CDS¸¦ ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS) ¹× Àü»çÀû ÀÚ¿ø °ü¸®(ERP) Ç÷§Æû°ú ÅëÇÕÇÏ´Â Ãß¼¼°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÇÇè½ÇÀÇ µðÁöÅÐ Àüȯ¿¡ ÀÖ¾î CDSÀÇ Àü·«Àû Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ¿¡¼­ CDS´Â ´õ ÀÌ»ó º¸Á¶ÀûÀÎ µµ±¸°¡ ¾Æ´Ñ Á¤È®¼º, ÄÄÇöóÀ̾ð½º, ¾÷¹« È¿À²¼ºÀ» º¸ÀåÇÏ´Â ÃֽŠºÐ¼® ¾÷¹«ÀÇ ±Ù°£ÀÌ µÇ´Â ±âµÕÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛÀÇ ´É·ÂÀ» ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ¿¡¼­ ±â´ëÇÏ´Â ±â´É°ú ¼º´ÉÀ» Å©°Ô º¯È­½ÃÄÑ ±âº»ÀûÀÎ ±â±â Á¦¾î¿Í µ¥ÀÌÅÍ ¼öÁýÀ» ³Ñ¾î Áö´ÉÀûÀ̰í È®Àå °¡´ÉÇÑ Ç÷§ÆûÀ¸·Î º¯¸ð½Ã۰í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý CDS ¼Ö·ç¼ÇÀº È®À强, ¿ø°Ý ¾×¼¼½º, À¯Áöº¸¼ö ¿ëÀ̼ºÀ¸·Î ÀÎÇØ ƯÈ÷ Áö¸®ÀûÀ¸·Î ºÐ»êµÈ ¿¬±¸½Ç°ú °øµ¿ ¿¬±¸ ÇÁ·ÎÁ§Æ®¸¦ ¼öÇàÇÏ´Â Á¶Á÷¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Å¬¶ó¿ìµå Áö¿ø Ç÷§ÆûÀº Áß¾Ó ÁýÁᫎ µ¥ÀÌÅÍ ÀúÀå¼Ò, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, °­È­µÈ »çÀ̹ö º¸¾È ÇÁ·ÎÅäÄÝÀ» Á¦°øÇϸç, Ãֽе¥ÀÌÅÍ °Å¹ö³Í½º Ç¥ÁØ¿¡ ÀûÇÕÇÕ´Ï´Ù. ÀΰøÁö´É°ú ¸Ó½Å·¯´×µµ ³»ÀåµÇ¾î ¿¹Ãø ºÐ¼®, ÀÚµ¿ ÇÇÅ© ½Äº°, ÀÌ»ó ¡ÈÄ °¨Áö, ¹æ¹ý·Ð ÃÖÀûÈ­¸¦ Á¦°øÇÏ¿© ºÐ¼®°¡ÀÇ ¾÷¹« ºÎ´ãÀ» Å©°Ô ÁÙÀ̰í ÀÇ»ç°áÁ¤ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º µðÀÚÀÎÀº ´õ¿í Á÷°üÀûÀÌ°í »ç¿ëÀÚ Á¤Àǰ¡ °¡´ÉÇØÁ® ´Ù¾çÇÑ ±â¼ú ¼öÁØÀÇ ¿¬±¸½Ç ´ã´çÀÚ°¡ º¸´Ù ºü¸£°Ô ¿Âº¸µùÇϰí È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °³¹æÇü ¾ÆÅ°ÅØÃ³¿Í API ÅëÇÕÀ» ÅëÇØ CDS´Â ELN, LIMS, QA/QC Ç÷§Æû µî ´Ù¸¥ ½ÇÇè½Ç ½Ã½ºÅÛ°ú ¿øÈ°ÇÏ°Ô Åë½ÅÇÒ ¼ö ÀÖ¾î »óÈ£¿¬°áµÈ ½ÇÇè½Ç »ýŰ踦 ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ð¹ÙÀÏ È£È¯¼º°ú ÅÍÄ¡½ºÅ©¸° ÀÎÅÍÆäÀ̽º¸¦ ÅëÇØ À¯¿¬¼º°ú Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ ºÐ¼®°¡°¡ ¿öÅ©Ç÷ο츦 ¸ð´ÏÅ͸µÇÏ°í ¿ø°ÝÀ¸·Î µ¥ÀÌÅ͸¦ °ËÅäÇÒ ¼ö ÀÖ´Â À¯¿¬¼º°ú Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù. ½Ç½Ã°£ °¨»ç ÃßÀû, ÀÚµ¿ ¹é¾÷ ½Ã½ºÅÛ, ¿ªÇÒ ±â¹Ý ¾×¼¼½º Á¦¾î¿Í °°Àº °­È­µÈ ÄÄÇöóÀ̾𽺠±â´ÉÀº ¾ö°ÝÇÑ ¼¼°è ±ÔÁ¦ ¿ä°Ç¿¡ ºÎÇÕÇϵµ·Ï º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, º¥´õµéÀº ƯÁ¤ ¾ÖÇø®ÄÉÀ̼ÇÀÇ ¿ä±¸¿Í ½ÇÇè½Ç ±Ô¸ð¿¡ µû¶ó ±â´ÉÀ» È®ÀåÇÒ ¼ö ÀÖ´Â ¸ðµâ½Ä ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î CDS´Â Á¤ÀûÀÎ µ¥ÀÌÅÍ ¼öÁý µµ±¸¿¡¼­ Å©·Î¸¶Åä±×·¡ÇÇ ¶óÀÌÇÁ»çÀÌŬ Àü¹Ý¿¡ °ÉÃÄ »ý»ê¼º, µ¥ÀÌÅÍ Ç°Áú ¹× ±ÔÁ¤ Áؼö¸¦ Çâ»ó½ÃŰ´Â ¿ªµ¿ÀûÀÎ Ç÷§ÆûÀ¸·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù.

¼¼°è Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ ¼ö¿ä¸¦ Çü¼ºÇÏ´Â Áö¿ª ¹× »ê¾÷ µ¿ÇâÀº?

Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â Áö¿ªº° ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, »ê¾÷ ¼ºÀå, ½ÇÇè½Ç »ýŰè Àü¹ÝÀÇ µðÁöÅÐ Çõ½Å ¼Óµµ¿¡ µû¶ó Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì, ƯÈ÷ ¹Ì±¹°ú ij³ª´Ù¿¡¼­´Â ÀǾàǰ °³¹ß ¹× Á¦Á¶ ½Ã µ¥ÀÌÅÍ ¹«°á¼º ¹× ¹®¼­È­¿¡ ´ëÇÑ ¾ö°ÝÇÑ FDA ±ÔÁ¤À¸·Î ÀÎÇØ Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à »ê¾÷ÀÌ ÁÖ¿ä °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼º¼÷ÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í ÀÚµ¿È­ ±â¼úÀÇ Àû±ØÀûÀÎ µµÀÔÀº ÇмúÀû, »ó¾÷Àû ȯ°æ¿¡¼­ CDSÀÇ ±¤¹üÀ§ÇÑ È®»êÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ½ºÀ§½º¿Í °°Àº ±¹°¡µéÀº ƯÈ÷ »ý¸í°úÇÐ, ½Äǰ¾ÈÀü, È­Çкм® ºÐ¾ß¿¡¼­ EMA Ç¥ÁØ ¹× ISO ÀÎÁõ Áؼö¸¦ Áß½ÃÇϰí ÀÖÀ¸¸ç, À¯·´ÀÌ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ±Þ¼ÓÇÑ »ê¾÷È­, Á¦¾à R&D ÅõÀÚ È®´ë, Á¤ºÎ ÁÖµµÀÇ Ç°Áú °ü¸® ÀÌ´Ï¼ÅÆ¼ºê°¡ Àεµ, Áß±¹, ÀϺ», Çѱ¹ µîÁö¿¡¼­ CDS µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡¿¡¼­´Â ½Å·ÚÇÒ ¼ö ÀÖ°í È®Àå °¡´ÉÇÑ µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛÀ» ÇÊ¿ä·Î ÇÏ´Â Á¦³×¸¯ ÀǾàǰ Á¦Á¶ ¹× À§Å¹ ¿¬±¸ ¾÷¹«°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿Àº ÇコÄɾî ÀÎÇÁ¶óÀÇ °³¼±, ǰÁú º¸Áõ ÇÁ·Î±×·¥ÀÇ ºÎ»ó, ´Ù±¹Àû Á¦¾à»çÀÇ ÁøÃâ·Î ÀÎÇØ ¼ºÀå ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. »ê¾÷º°·Î´Â ÀǾàǰ ¿Ü¿¡µµ ȯ°æ ¸ð´ÏÅ͸µ ºÎ¹®ÀÌ Á¤È®ÇÑ °Ë»ç ¹× ¿À¿° ¹æÁö¸¦ À§ÇÑ ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ CDS¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ¼®À¯È­ÇÐ »ê¾÷Àº °øÁ¤ °ËÁõ ¹× ǰÁú ºÐ¼®¿¡ CDS¸¦ »ç¿ëÇϸç, ½ÄÀ½·á ºÎ¹®Àº ¿À¿° °Ë»ç ¹× ¿µ¾ç ÇÁ·ÎÆÄÀϸµ¿¡ CDS¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû, ºÎ¹®º° ¿ªÇаü°è´Â °í±Þ ºÐ¼® ȯ°æ¿¡¼­ Àϰü¼º, ÃßÀû¼º, ¼º´ÉÀ» Á¦°øÇÒ ¼ö ÀÖ´Â Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿ä±¸°¡ ´Ù¾çÇØÁö°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

¼¼°è CDS ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Å©·Î¸¶Åä±×·¡ÇÇ µ¥ÀÌÅÍ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ±ÔÁ¦ ÁøÈ­, ½ÇÇè½Ç ÀÚµ¿È­, µðÁöÅÐ ÅëÇÕ, ³ôÀº ºÐ¼® 󸮷®¿¡ ´ëÇÑ ¿ä±¸ µî ¿©·¯ °¡Áö º¹ÇÕÀûÀÎ ¿äÀο¡ ÀÇÇØ ÃËÁøµÉ °ÍÀÔ´Ï´Ù. °¡Àå Å« ¿øµ¿·Â Áß Çϳª´Â FDA, EMA, ICH µîÀÇ ±â°üÀÌ °ü¸®ÇÏ´Â »ê¾÷ Àü¹Ý¿¡ °ÉÃÄ µ¥ÀÌÅÍ ¹«°á¼º ¹× ÄÄÇöóÀ̾𽺠¿ä±¸»çÇ×ÀÌ °­È­µÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. CDS Ç÷§ÆûÀº 21 CFR Part 11, Annex 11 ¹× ALCOA+ÀÇ ¿øÄ¢À» ÃæÁ·Çϵµ·Ï ¼³°èµÇ¾î ±ÔÁ¦ ȯ°æ¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Å©·Î¸¶Åä±×·¡ÇÇ ºÐ¼®ÀÇ º¹À⼺°ú ½Ã·áÀÇ ¾çÀÌ Áõ°¡ÇÔ¿¡ µû¶ó µ¥ÀÌÅÍ ¼öÁý, ÇÇÅ© ó¸®, º¸°í¼­ ÀÛ¼ºÀ» ÀÚµ¿È­ÇÏ°í ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÁÙÀ̰í ÀçÇö¼ºÀ» Çâ»ó½ÃŰ´Â CDS¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÇÇè½Ç ¿öÅ©Ç÷οìÀÇ µðÁöÅÐ ÀüȯÀ» ÃßÁøÇÏ´Â °Íµµ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, Á¶Á÷Àº ´õ ³ªÀº ÀÇ»ç°áÁ¤°ú ÀÚ¿ø ÃÖÀûÈ­¸¦ À§ÇØ À̱âÁ¾ Àåºñ¿Í µ¥ÀÌÅÍ ½ºÆ®¸²À» ÅëÇÕ Ç÷§ÆûÀ¸·Î ÅëÇÕÇÏ·Á°í ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ßÀÇ R&D ÅõÀÚ Áõ°¡´Â ƯÈ÷ ÀÓ»ó½ÃÇè, ¾à¹° ¾ÈÁ¤¼º ½ÃÇè, »ý¹°ÇÐÀû Á¦Á¦ °³¹ß¿¡¼­ CDSÀÇ »ç¿ë ¹üÀ§¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½Äǰ ¾ÈÀü ¹× ȯ°æ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ Ç°Áú º¸ÁõÀÇ Á߿伺Àº CDS ¼Ö·ç¼ÇÀÌ µ¶ÀÚÀûÀ¸·Î Á¦°øÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅÍ ¼öÁý ¹× ÃßÀû °¡´É¼º¿¡ ´ëÇÑ Çʿ伺À» °­È­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ °¡¼ÓÈ­µÇ°í ÀÖ´Â ¿ø°Ý ¹× ºÐ»êÇü ½ÇÇè½Ç·ÎÀÇ ÀüȯÀº Ŭ¶ó¿ìµå ±â¹ÝÀÇ À¥ Á¢±ÙÀÌ °¡´ÉÇÑ CDS Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. »ç¿ëÀÚ °æÇè ¼³°è, ¸Ó½Å·¯´×, ¸ðµâ½Ä Àü°³ ¸ðµ¨ÀÇ ¹ßÀüÀ¸·Î CDS ¼Ö·ç¼ÇÀº Áß¼Ò±Ô¸ðÀÇ °Ë»ç½Ç¿¡¼­µµ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀ» Á¾ÇÕÇϸé, CDS ½ÃÀåÀº È®´ëµÇ°í ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó Çö´ë ºÐ¼® °úÇп¡¼­ Á¤È®¼º, ±ÔÁ¤ Áؼö ¹× ¿î¿µ ¿ì¼ö¼ºÀ» ½ÇÇöÇÏ´Â Áß¿äÇÑ ¼ö´ÜÀ¸·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(CDS ¼ÒÇÁÆ®¿þ¾î, CDS ¼­ºñ½º), À¯Çü(µ¶¸³Çü CDS, ÅëÇÕ CDS), Àü°³(¿ÂÇÁ·¹¹Ì½º Àü°³, Ŭ¶ó¿ìµå ±â¹Ý Àü°³), ¿ëµµ(Drug Discovery¡¤¿¬±¸°³¹ß ¿ëµµ, ǰÁú °ü¸®¡¤½ÃÇè ¿ëµµ, ½Äǰ ¹× À½·á ½ÃÇè ¿ëµµ, ȯ°æ ½ÃÇè ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿À ±â¾÷ ÃÖÁ¾ ¿ëµµ, Çмú¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Chromatography Data Systems (CDS) Market to Reach US$772.4 Million by 2030

The global market for Chromatography Data Systems (CDS) estimated at US$504.1 Million in the year 2024, is expected to reach US$772.4 Million by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. CDS Software, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$544.0 Million by the end of the analysis period. Growth in the CDS Services segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$137.3 Million While China is Forecast to Grow at 11.7% CAGR

The Chromatography Data Systems (CDS) market in the U.S. is estimated at US$137.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$164.7 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Chromatography Data Systems (CDS) Market - Key Trends & Drivers Summarized

Why Are Chromatography Data Systems Gaining Prominence in Modern Laboratory Environments?

Chromatography Data Systems (CDS) have become essential tools in analytical laboratories worldwide due to the increasing complexity of chromatographic processes and the rising need for regulatory compliance, data integrity, and workflow automation. CDS software acts as the nerve center for chromatographic instruments by collecting, processing, and storing data from instruments such as HPLC, GC, and UHPLC, streamlining the entire workflow from sample injection to result reporting. The growing demand for high-throughput analysis in pharmaceutical, biotechnology, food and beverage, environmental testing, and petrochemical sectors is amplifying the role of CDS as a facilitator of accurate, reproducible, and regulatory-compliant data analysis. Laboratories are transitioning away from manual data logging and fragmented systems in favor of integrated CDS platforms that support multi-instrument control, centralized data management, and advanced analytics. The increasing scrutiny by regulatory bodies such as the FDA, EMA, and ISO has further emphasized the importance of audit trails, electronic signatures, and secure data storage, all of which CDS platforms provide. In addition, as laboratories adopt lean practices to reduce turnaround time and increase efficiency, CDS serves as a critical enabler of streamlined workflows and standardized procedures. The growing trend of integrating CDS with Laboratory Information Management Systems (LIMS) and Enterprise Resource Planning (ERP) platforms highlights their strategic importance in laboratory digital transformation. In this environment, CDS is no longer seen as a supplementary tool but rather as a foundational pillar of modern analytical operations that ensures accuracy, compliance, and operational efficiency.

How Are Technology Advancements Transforming the Capabilities of Chromatography Data Systems?

Technological advancements are significantly reshaping the capabilities and performance expectations of Chromatography Data Systems, transforming them into intelligent, scalable platforms that go beyond basic instrument control and data acquisition. Cloud-based CDS solutions are gaining traction due to their scalability, remote accessibility, and ease of maintenance, particularly for organizations with geographically distributed labs or collaborative research projects. These cloud-enabled platforms offer centralized data repositories, real-time monitoring, and enhanced cybersecurity protocols, making them well-suited for modern data governance standards. Artificial intelligence and machine learning are also being incorporated to provide predictive analytics, automated peak identification, anomaly detection, and method optimization, which significantly reduce analyst workload and improve decision-making accuracy. User interface designs are becoming more intuitive and customizable, enabling faster onboarding and greater efficiency for laboratory personnel with varying skill levels. The adoption of open architecture and API integrations allows CDS to seamlessly communicate with other lab systems such as ELNs, LIMS, and QA/QC platforms, creating an interconnected laboratory ecosystem. Furthermore, mobile compatibility and touchscreen interfaces are increasing flexibility and accessibility, enabling analysts to monitor workflows and review data remotely. Enhanced compliance features such as real-time audit trails, automated backup systems, and role-based access controls are ensuring alignment with stringent global regulatory requirements. Additionally, vendors are offering modular solutions that allow users to scale functionality based on specific application needs and laboratory size. These advancements are transforming CDS from static data acquisition tools into dynamic platforms that enhance productivity, data quality, and compliance across the entire chromatographic lifecycle.

What Regional and Industry Trends Are Shaping Demand for Chromatography Data Systems Worldwide?

The global demand for Chromatography Data Systems is shaped by region-specific regulatory frameworks, industrial growth, and the pace of digital transformation across laboratory ecosystems. In North America, especially in the United States and Canada, the pharmaceutical and biopharmaceutical industries are major drivers due to stringent FDA regulations on data integrity and documentation in drug development and manufacturing. The region’s mature research infrastructure and aggressive adoption of automation technologies support widespread CDS deployment in both academic and commercial settings. Europe follows closely, with countries like Germany, the UK, and Switzerland emphasizing compliance with EMA standards and ISO certifications, particularly in life sciences, food safety, and chemical analysis. In Asia-Pacific, rapid industrialization, growing investment in pharmaceutical R&D, and government-led quality control initiatives are pushing the adoption of CDS across India, China, Japan, and South Korea. These countries are also home to expanding generics manufacturing and contract research operations that require reliable and scalable data management systems. Latin America and the Middle East are emerging as growth markets, driven by improvements in healthcare infrastructure, the rise of quality assurance programs, and the entry of multinational pharmaceutical companies. Industry-wise, apart from pharmaceuticals, the environmental monitoring sector is adopting CDS to ensure accurate testing and regulatory compliance in pollution control. The petrochemical industry uses CDS for process validation and quality analysis, while the food and beverage sector relies on it for contamination checks and nutritional profiling. These regional and sectoral dynamics indicate a growing, diversified need for chromatography data systems that can deliver consistency, traceability, and performance in high-stakes analytical environments.

What Core Drivers Are Propelling Growth in the Global CDS Market?

The growth in the Chromatography Data Systems market is driven by several interlinked factors stemming from regulatory evolution, laboratory automation, digital integration, and the need for higher analytical throughput. One of the foremost drivers is the tightening of data integrity and compliance requirements across industries governed by agencies such as the FDA, EMA, and ICH. CDS platforms are designed to fulfill 21 CFR Part 11, Annex 11, and ALCOA+ principles, making them indispensable in regulated environments. The increasing complexity of chromatographic analyses, coupled with growing sample volumes, is also fueling demand for CDS that can automate data acquisition, peak processing, and reporting, reducing manual errors and improving reproducibility. The push for digital transformation in laboratory workflows is another significant factor, with organizations looking to integrate disparate instruments and data streams into unified platforms for better decision-making and resource optimization. Rising R&D investments in pharmaceuticals and biotechnology are expanding the scope of CDS use, particularly in clinical trials, drug stability studies, and biologics development. The global emphasis on quality assurance, especially in food safety and environmental monitoring, is reinforcing the need for reliable data capture and traceability, which CDS solutions are uniquely equipped to provide. Additionally, the shift toward remote and decentralized laboratories, accelerated by the COVID-19 pandemic, is creating demand for cloud-based and web-accessible CDS platforms. Advances in user experience design, machine learning, and modular deployment models are making CDS solutions more accessible to small and mid-sized laboratories. Altogether, these drivers are not only expanding the CDS market but also transforming it into a critical enabler of accuracy, compliance, and operational excellence in modern analytical science.

SCOPE OF STUDY:

The report analyzes the Chromatography Data Systems (CDS) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (CDS Software, CDS Services); Type (Standalone CDS, Integrated CDS); Deployment (On-Premise Deployment, Cloud-based Deployment); Application (Drug Discovery & Development Application, Quality Control & Testing Application, Food & Beverages Testing Application, Environmental Testing Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Academic Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â